芪白平肺胶囊对慢性阻塞性肺疾病肺血管收缩大鼠肺功能及内皮素水平-1、缺氧诱导因子-1α的影响

Effect of Qibai Pingfei Capsule on Chronic Obstructive Pulmonary Disease and Pulmonary Vascular Contraction of Rat Lung Function,Endothelin 1( ET-1) and Hypoxia Inducing Factor 1α( HIF-1α)

目的研究芪白平肺胶囊对慢性阻塞性肺疾病肺血管收缩大鼠肺功能及内皮素水平-1(ET-1)、缺氧诱导因子-1α(HIF-1α)的影响及其机制。方法将60只Wistar大鼠随机分为正常组、模型组、芪白平肺胶囊预防组、尼可地尔预防组、芪白平肺胶囊治疗组、尼可地尔治疗组,每组10只,采用复合因素造模方法建立慢性阻塞性肺疾病肺血管收缩大鼠模型,给予芪白平肺胶囊及西药尼可地尔灌胃,观察大鼠的一般情况,测定各组大鼠第0.3s用力呼气量(FEV 0.3)、用力肺活量(FVC)、第0.3 s用力呼气量与用力肺活量的比值(FEV 0.3/FVC)、呼气峰流速(PEF)以及用酶联免疫吸附法测定血清ET-1,Hif-1α含量。结果模型组较正常对照组血清ET-1、Hif-1α显著提高(P<0.01);肺功能FEV 0.3、FVC、FEV 0.3/FVC、PEF显著下降(P<0.01),各预防及治疗组与模型组均有统计学意义(P<0.01或P<0.05),但芪白平肺胶囊预防组较模型组差异更显著(P<0.01),芪白平肺胶囊预防组与正常组无统计学意义(P>0.05),并且明显优于芪白平肺治疗组。结论芪白平肺胶囊早期预防可改善慢性阻塞性肺疾病肺血管收缩大鼠肺功能,降低ET-1、Hif-1α含量从而达到治疗慢性阻塞性肺疾病肺血管收缩的作用。

Objective To study the effect and mechanism of Qibai Pingfei Capsule on chronic obstructive pulmonary disease and pulmonary vascular contraction of rat lung function, endothelin 1 （ET-1） and hypoxia inducing factor la （HIF-1α）. Methods 60 wistar rats were randomly divided into normal group, model group, Qibai Pingfei Capsule prevention group, nicorandil prevention group, Qibai Pingfei Capsule treatment group, nicorandil treatment group, with 10 in each group. Composite factors building method was adopted to establish the pulmonary vasoconstriction rat model with chronic obstructive pul- monary disease, and Qibai Pingfei Capsule was given and western medicine nicorandil tablets were used for intragastric ad- ministration. And then the general condition of rats was observed, forced expiratory volume at second 0.3 （FEV0.3）, forced vital capacity （FVC）, forced expiratory volume at second 0.3 （FEV0.3/FVC） and forced vital capacity ratio, peak expirato- ry flow （PEF） were measured, and serum levels of ET-1, Hif-1α content were determined by enzyme linked immunosorbentmethod. Results Compared with normal control group, the model group＇s serum levels of ET-1 and Hif-1α increased significantly （ P 〈 0.01 ） ; lung function FEV0.3, FVC, FEV00.3/FVC, PEF decreased significantly （ P 〈 0.01 ）. All the prevention and the treatment groups were different from the model group （ P 〈 0.01 or P 〈 0.05）. However, the difference between the Qibai Pingfei Capsule prevention group and the model group was more significant （P 〈 0.01 ）. There was no difference between Qibai Pingfei Capsule prevention group and normal group （ P 〉 0.05）, and Qibai Pingfei Capsule prevention group was superior to qibaipingfei treatment group. Condusion Qibai Pingfei Capsule can be used for early prevention, which can improve chronic obstructive pulmonary disease and pulmonary vascular contraction of rat Lung function, reduce ET- 1 and Hif-1α content so as to achieve the treatment effect of chronic obstructive pulmonary disease and pulmonary vasoconstriction.